Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06162221 · ClinicalTrials.gov registry record · Phase 1

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

A Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and KRAS, NRAS, HRAS-mutated NSCLC, sponsored by Revolution Medicines.

Recruiting
Registry status
Phase 1
Development phase
616
Enrollment target
20
Study locations

NCT06162221 is a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and KRAS, NRAS, HRAS-mutated NSCLC that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 616 participants, above the 278-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (122% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06162221, a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and KRAS, NRAS, HRAS-mutated NSCLC, is actively recruiting participants, sponsored by Revolution Medicines.

RECRUITING
Registry status
Phase 1
Development phase
616 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805

Conditions Studied

Non-small Cell Lung Cancer (NSCLC) KRAS, NRAS, HRAS-mutated NSCLC KRAS G12C-mutated Solid Tumors, Lung Cancer Lung Cancer Stage IV, Advanced Solid Tumor, Cancer RAS G12D-mutated NSCLC

Interventions

  • DRUG Pembrolizumab
  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG RMC-6291
  • DRUG RMC-6236

Study Locations (20)

California

  • City of Hope - Duarte - Duarte
  • City of Hope - Lennar - Irvine
  • UC Davis, Davis Comprehensive Cancer Center - Sacramento
  • University of California, San Diego Moores Cancer Center - San Diego
  • UCSF Medical Center - Mission Bay - San Francisco
  • Stanford University - Stanford Cancer Institute - Stanford

New York

  • New York University Langone Health - New York
  • Icahn School of Medicine at Mount Sinai - New York
  • Columbia University Medical Center - New York
  • Clinical Research Alliance - Westbury

Florida

  • Boca Raton Clinical Research Associates - Plantation
  • Cancer Specialists of North Florida - Saint Augustine
  • H Lee Moffitt Cancer Center and Research Institute - Tampa

Arizona

  • Banner MD Anderson Cancer Center - Gilbert

District of Columbia

  • Georgetown University Medical Center - Washington D.C.

Massachusetts

  • Dana Farber Cancer Institute - Boston

Michigan

  • Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) - Detroit

Montana

  • Intermountain Health - St. Vincent Frontier Cancer Center - Billings

Trial Details

FieldValue
Enrollment Target 616 participants
Start Date 2024-01-18
Est. Completion 2028-12
Phase Phase 1

Sponsor

Revolution Medicines

16 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06162221

The ClinicalTrials.gov registry entry for NCT06162221 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 616 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 278-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (122% higher). The listed sponsor is Revolution Medicines, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT06162221 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, New York, Florida.

Frequently Asked Questions

What is clinical trial NCT06162221 about?

NCT06162221 is a clinical study titled "Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC". The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subpr...

What is the current status of trial NCT06162221?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 616 participants. The study started on 2024-01-18. Estimated completion is 2028-12.

What conditions does trial NCT06162221 study?

This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC), KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC.

What interventions are being tested in trial NCT06162221?

The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), RMC-6291 (DRUG), RMC-6236 (DRUG).

Who is sponsoring clinical trial NCT06162221?

This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06162221 being conducted?

This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-small Cell Lung Cancer (NSCLC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-small Cell Lung Cancer (NSCLC)

All registered trials for this condition

KRAS, NRAS, HRAS-mutated NSCLC

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.